METTL3 and gastric cancer: METTL3 has been shown to activate the AKT/mTOR pathway by targeting the inhibition of PTEN/TMEM127 expression through m6A modification at the pri-mir-17-92 A879 site, promoting growth and metastasis of GC [75].